38.000

- (-%)
Range 37.950 - 38.010   (0.16%)
Open 37.990
Previous Close 38.000
Buy Price -
Buy Volume 11
Sell Price -
Sell Volume 9
Volume 935,834
Value -
Remark
Measurement Type Value
EPS (USD) -1.811
Trailing EPS (USD) -1.811
NAV (USD) 5.692
Cash In Hand (USD) 1.491
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 6.674
Price / Cash In Hand 25.486
Issued & Paid-up Shares 46,572,000
Treasury Shares -
Market Cap (M) 1,769.27
Par Value (USD) n.a.
Beta - 75 Days -0.369
R-Squared - 75 Days(%) 0.56
Beta - 500 Days 1.269
R-Squared - 500 Days(%) 2.96
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 16 Apr 2021 04:00.
Data powered by
View All Events

About FIVE PRIME THERAPEUTICS

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. Protein therapeutics is antibodies or drugs developed from extracellular proteins or protein fragments that block disease processes, including cancer and inflammatory diseases. The Company�s advanced product candidates include FP-1039/GSK3052230 (FP-1039), FPA008 and FPA144. FP-1039 is a protein therapeutic that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), and is being developed to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). FPA144 is an antibody that inhibits FGF receptor 2b (FGFR2b), and is being developed to treat patients with gastric cancer and potentially other solid tumors.

Loading Chart...